Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020475

CHIEF FINANCIAL OFFICER sold 5,250 shares at an average $26.68 ($140,052)

  • CHIEF FINANCIAL OFFICER acquired 5,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-07-29 Exercise or conversion : show line 1 in the form 10b5-1 +5,250 $2.48 $13,020 5,250 D
2024-07-29 Sale : show line 2 in the form 10b5-1 −5,189 $26.67 $138,378 61 D
2024-07-29 Sale : show line 3 in the form 10b5-1 −61 $27.44 $1,674 0 D
Open-market sales · 5,250 sh · avg $26.68 · $140,052

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-07-29 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −5,250 204,370 D
Loading xslF345X05/form4-07312024_110716.xml…